OTCMKTS:NWBO Northwest Biotherapeutics (NWBO) Stock Price, News & Analysis → Better than Bitcoin? The Biotech Stock with 46,751% Potential (From Behind the Markets) (Ad) Free NWBO Stock Alerts $0.48 +0.02 (+4.38%) (As of 04/25/2024 ET) Add Compare Share Share Today's Range$0.46▼$0.4950-Day Range$0.46▼$0.6152-Week Range$0.40▼$1.09Volume1.10 million shsAverage Volume1.72 million shsMarket Capitalization$574.33 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartEarningsFinancialsHeadlinesSEC FilingsShort InterestStock AnalysisChartEarningsFinancialsHeadlinesSEC FilingsShort Interest Get Northwest Biotherapeutics alerts: Email Address Ad Behind the MarketsBetter than Bitcoin? The Biotech Stock with 46,751% Potential4x Better than Bitcoin Bitcoin would have to go from $68,000 to $314,000 to match the 463% gains we saw with Immunogen in December.Get the name of the stock here >>> About Northwest Biotherapeutics Stock (OTCMKTS:NWBO)Northwest Biotherapeutics, Inc., a biotechnology company, develops personalized immune therapies for cancer in the United States and internationally. The company develops its products based on DCVax, a platform technology that uses activated dendritic cells to mobilize a patient's own immune system to attack cancer. Its lead product, DCVax-L, which has completed Phase III clinical trials to treat Glioblastoma multiforme brain cancer. The company also develops DCVax-Direct, which is in Phase I/II clinical trials to treat inoperable solid tumors. The company was founded in 1996 and is headquartered in Bethesda, Maryland.Read More NWBO Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart NWBO Stock News HeadlinesApril 24, 2024 | americanbankingnews.comNorthwest Biotherapeutics (OTCMKTS:NWBO) Stock Price Crosses Below 200-Day Moving Average of $0.65April 16, 2024 | americanbankingnews.comNorthwest Biotherapeutics (OTCMKTS:NWBO) Stock Passes Below 200-Day Moving Average of $0.67April 25, 2024 | Stansberry Research (Ad)Mysterious Gold Leverage Just AnnouncedWorld's biggest multibillionaire investor group is buying THIS by the tons Most folks have completely missed the fact that there's one group of investors so powerful they're literally buying ONE THING by the tons… Stacking it in their locked vaults on pallets in record numbers.March 21, 2024 | prnewswire.comNorthwest Biotherapeutics Appoints Seasoned Business Executive and Investor To Its Board of DirectorsMarch 2, 2024 | ft.com‘Spoofing’ case might draw back curtain on high-speed trading firmsFebruary 29, 2024 | uk.finance.yahoo.comNorthwest Biotherapeutics, Inc. (NWBO)February 23, 2024 | benzinga.comNorthwest Biotherapeutics Stock (OTC:NWBO), Short Interest ReportFebruary 7, 2024 | finance.yahoo.comNorthwest Biotherapeutics Moves From Optimization of Flaskworks Prototype to Fabrication of GMP-Compliant Units For Installation, Validation and Final Testing Prior to Regulatory CertificationApril 25, 2024 | Stansberry Research (Ad)Mysterious Gold Leverage Just AnnouncedWorld's biggest multibillionaire investor group is buying THIS by the tons Most folks have completely missed the fact that there's one group of investors so powerful they're literally buying ONE THING by the tons… Stacking it in their locked vaults on pallets in record numbers.December 22, 2023 | msn.comNorthwest Biotherapeutics submits marketing application to UK MHRA for DCVax-LDecember 21, 2023 | finanznachrichten.deNorthwest Biotherapeutics Announces That A Marketing Authorization Application Has Been Submitted To The UK MHRA For DCVax-L For GlioblastomaDecember 21, 2023 | finance.yahoo.comNorthwest Biotherapeutics Announces That A Marketing Authorization Application Has Been Submitted To The UK MHRA For DCVax®-L For GlioblastomaNovember 22, 2023 | finance.yahoo.comNorthwest Biotherapeutics Provides Update On Final Preparations For Marketing Authorization ApplicationOctober 31, 2023 | morningstar.comNorthwest Biotherapeutics Inc NWBOOctober 14, 2023 | msn.comNorthwest Bio: Another Small Filing DelayOctober 13, 2023 | seekingalpha.comNW Bio dips on announcing delay in submission of marketing application for DCVaxOctober 13, 2023 | marketwatch.comNorthwest Biotherapeutics Shares Slide on Application DelayOctober 13, 2023 | finance.yahoo.comNorthwest Biotherapeutics Provides Update On Near Term Plans For Submission of Marketing Authorization ApplicationSeptember 12, 2023 | finance.yahoo.comNorthwest Biotherapeutics Announces That Dr. Linda Liau Has Joined The Company's Scientific Advisory BoardAugust 17, 2023 | msn.comNorthwest Bio: Is There Ever Going To Be A Right Time?August 6, 2023 | usnews.comNorthwest Missouri State UniversityAugust 4, 2023 | health.usnews.comNorthwest HospitalJuly 15, 2023 | thestreet.comWhy Northwest Bio Is Shunned by Savvy Health Care InvestorsJune 19, 2023 | pnj.comThree rounds of severe weather expected over the next 24 hours for Northwest FloridaJune 13, 2023 | health.usnews.comHCA Houston Healthcare NorthwestMay 27, 2023 | finance.yahoo.comNWBO - Northwest Biotherapeutics, Inc.May 9, 2023 | thestreet.comNorthwest Bio Warns FDA May Throw Out Phase III Brain Cancer StudySee More Headlines Receive NWBO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Northwest Biotherapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/05/2024Today4/25/2024Next Earnings (Estimated)5/08/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolOTCMKTS:NWBO Previous SymbolNASDAQ:NWBO CUSIPN/A CIK1072379 Webwww.nwbio.com Phone(240) 497-9024Fax240-627-4121Employees25Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($0.06) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-62,600,000.00 Net Margins-3,240.11% Pretax Margin-3,240.11% Return on EquityN/A Return on Assets-207.51% Debt Debt-to-Equity RatioN/A Current Ratio0.09 Quick Ratio0.09 Sales & Book Value Annual Sales$1.93 million Price / Sales297.27 Cash FlowN/A Price / Cash FlowN/A Book Value($0.06) per share Price / Book-7.94Miscellaneous Outstanding Shares1,204,040,000Free Float1,090,800,000Market Cap$573.73 million OptionableNot Optionable Beta-0.68 7 Energy Stocks to Buy and Hold ForeverDo you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.Get This Free Report Key ExecutivesMs. Linda F. Powers J.D. (Age 68)Chairperson, CEO, President, CFO & Chief Accounting Officer Comp: $1.1MDr. Alton L. Boynton Ph.D. (Age 79)Founder, Chief Scientific Officer, Secretary & Director Comp: $450kDr. Marnix L. Bosch M.B.A. (Age 65)Ph.D., Chief Technical Officer Comp: $597.5kMr. Leslie J. Goldman (Age 79)Senior VP & General Counsel Comp: $825kMs. Jean M. Davis (Age 52)Chief Information Officer Comp: $258.78kMr. David InnesVice President of Investor RelationsMr. Pankaj R. Shah C.A.CPA, Financial ControllerMore ExecutivesKey CompetitorsMineralys TherapeuticsNASDAQ:MLYSOlema PharmaceuticalsNASDAQ:OLMAVerve TherapeuticsNASDAQ:VERVPhibro Animal HealthNASDAQ:PAHCCureVacNASDAQ:CVACView All Competitors NWBO Stock Analysis - Frequently Asked Questions How have NWBO shares performed in 2024? Northwest Biotherapeutics' stock was trading at $0.7010 at the beginning of the year. Since then, NWBO shares have decreased by 32.0% and is now trading at $0.4765. View the best growth stocks for 2024 here. When is Northwest Biotherapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 8th 2024. View our NWBO earnings forecast. How were Northwest Biotherapeutics' earnings last quarter? Northwest Biotherapeutics, Inc. (OTCMKTS:NWBO) announced its earnings results on Tuesday, March, 5th. The biotechnology company reported ($0.02) EPS for the quarter. The biotechnology company had revenue of $0.45 million for the quarter. What other stocks do shareholders of Northwest Biotherapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Northwest Biotherapeutics investors own include Clearside Biomedical (CLSD), Ocular Therapeutix (OCUL), Melinta Therapeutics (MLNT), (ZLTQ) (ZLTQ), Avid Bioservices (CDMO), Idera Pharmaceuticals (IDRA), Amarin (AMRN), Inovio Pharmaceuticals (INO) and MEI Pharma (MEIP). How do I buy shares of Northwest Biotherapeutics? Shares of NWBO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (OTCMKTS:NWBO) was last updated on 4/25/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThe Best AI Stock to Own in the World Today is Trading for Just $25Banyan Hill PublishingThese AI trades triggered this morning (545% return)Prosper Trading AcademyThe A.I. story nobody is telling you (Read ASAP)TradeSmithHe Is Giving Away BitcoinCrypto Swap ProfitsJim Cramer’s “The Biggest Drug Ever”Behind the MarketsYour Money is Not SafeAmerican AlternativeThe AI stock to buy right nowStockEarnings Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Northwest Biotherapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
